Media headlines about Minerva Neurosciences (NASDAQ:NERV) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Minerva Neurosciences earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 47.1363398137756 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:
- Jefferies Group Comments on Minerva Neurosciences Inc’s Q1 2018 Earnings (NERV) (americanbankingnews.com)
- Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates – GlobeNewswire (press release) (globenewswire.com)
- Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and … – Nasdaq (nasdaq.com)
- Minerva Neurosciences Inc NASDAQ:NERV And Mistras Group Inc NYSE:MG are reporting this earnings, what to expect. (stockmarketdaily.co)
Several equities analysts recently weighed in on the company. BidaskClub upgraded Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. ValuEngine downgraded Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $12.92.
In related news, CFO Geoff Race sold 5,829 shares of the business’s stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $5.79, for a total value of $33,749.91. Following the sale, the chief financial officer now directly owns 197,698 shares in the company, valued at $1,144,671.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 12,590 shares of company stock worth $73,073 over the last quarter. 21.60% of the stock is owned by company insiders.
WARNING: “Minerva Neurosciences (NASDAQ:NERV) Earning Somewhat Positive News Coverage, Accern Reports” was published by BBNS and is the sole property of of BBNS. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/14/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-minerva-neurosciences-nerv-stock-price/1924920.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.